VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
KYTX
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
KYTXKyverna Therapeutics, Inc.
$4.70$286M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
KYTX logo

Kyverna Therapeutics, Inc.

KYTX
NASDAQ · Cell & Gene Therapy
$4.70
At close - Nov 17, 4:00 PM EST - USD
Market Cap$286M
P/E-1.8x
52W High$13.67
Volume616.41K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q2

Pre-Revenue Cash Burn Erodes Liquidity Buffer

Kyverna Therapeutics is a pre-commercial biotechnology company with zero revenue, entirely dependent on external financing to fund its pipeline. The investment thesis hinges on the successful clinical development and potential commercialization of its therapies, but the primary risk is the sustainability of its cash…

GrowthStable
ProfitabilityNegative
ValuationReview
TechnicalsWeak
Explore valuation models
MARKET ACTION

KYTX price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

8/12 Beats

EPS beat 8 of last 12 quarters

02

Valuation risk

-105% Peers

P/E is 105% below peer median

03

Market leadership

RS 19 · Lag

Laggard (Underperforming 81% of market)

04

Weak Trend

Below 200DMA

Price < 200DMA

Next CatalystEstimated earnings · Feb 12

Market performance

Price History →

Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
KYTX-46.41%
S&P 500 (^GSPC)+7.21%
1-Year Return
KYTX-34.36%
S&P 500 (^GSPC)+10.03%
3-Year Return
KYTX-84.33%
S&P 500 (^GSPC)+61.53%
5-Year Return
KYTX-84.33%
S&P 500 (^GSPC)+55.21%

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
-
Net income FY25
-$161M-26.5% YoY
Free cash flow FY25
-$154M-32.0% YoY
Operating margin FY25
-
ROIC (FY25)-80.8%
Avg ROIC 5Y-93.4%
ROE (TTM)-86.9%
Piotroski Score2 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate8/12 (67%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Nov 12, 2026
-$0.68+1.6%
vs -$0.69
—
vs —
Q3 2026
Aug 12, 2026
-$0.63+7.1%
vs -$0.68
—
vs —
Q2 2026
May 12, 2026
-$0.66+12.0%
vs -$0.75
—
vs —
Q2 2026
Mar 26, 2026
-$0.80+5.3%
vs -$0.84
—
vs —
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
PRNewsWire·5d ago
Did Kyverna Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

GlobeNewsWire·6d ago
Kyverna Therapeutics Announces Completion of BLA Submission for Miv-cel in Stiff Person Syndrome and Reports Third Quarter 2026 Financial Results

BLA submission for miv-cel in SPS completed with request for priority review  Commercial readiness advancing for potential U.S. launch of miv-cel, which would become the first approved therapy for SPS and first approved CAR-T therapy in autoimmune disease KYSA-6 Phase 3 gMG trial enrollment on-track for completion in mid-2027 Miv-cel's clinical profile continues to set the benchmark for autoimmune CAR T, demonstrating durable clinical benefit and a consistent, well-tolerated safety profile across multiple neurologic autoimmune indications EMERYVILLE, Calif., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical immunology company pioneering transformative therapies for people with neurologic autoimmune diseases, today reported portfolio progress and financial results for the third quarter ended September 30, 2026.

GlobeNewsWire·Nov 9, 2026
Kyverna Therapeutics Announces Publication of Registrational Miv-cel Data in Patients with Stiff Person Syndrome in JAMA Neurology

Publication reinforces miv-cel's potential to deliver durable clinical benefit with a single dose, enabled by miv-cel's unique construct, and become the first approved therapy in SPS and first approved CAR T-cell therapy for autoimmune disease

GlobeNewsWire·Nov 5, 2026
Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference

EMERYVILLE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical immunology company pioneering transformative therapies for people with neurologic autoimmune diseases, today announced that company management will present at the Jefferies Global Healthcare Conference in London, United Kingdom on Thursday, November 19, 2026, at 10:00 am GMT.

Filtered for Kyverna Therapeutics, Inc.More Headlines
04

Compare before deciding

Benchmark KYTX against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Kyverna Therapeutics, Inc. (KYTX)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
KYTX logoKYTXKyverna Therapeutics, Inc.Current
$4.70$285.74M-1.85——-86.87%—
CABA logoCABACabaletta Bio, Inc.
$1.02$166.32M-1.01——-106.78%—
AUTL logoAUTLAutolus Therapeutics plc
$1.09$290.1M-1.13646.68%-186.32%-263.11%—
IMVT logoIMVTImmunovant, Inc.
$33.21$6.85B-13.49—-7173.52%-63.01%—
BEAM logoBEAMBeam Therapeutics Inc.
$20.65$2.12B-20.19120.01%-73.04%-9.69%—
LEGN logoLEGNLegend Biotech Corporation
$16.11$2.98B-9999.0064.04%-0.02%-0.02%—

Compare KYTX vs Peers

Kyverna Therapeutics, Inc. (KYTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs CABA

Most directly comparable listed peer for KYTX.

Scale Benchmark

vs ABBV

Larger-name benchmark to compare KYTX against a more recognizable public peer.

Peer Set

Compare Top 5

vs CABA, AUTL, IMVT, BEAM

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

KYTX SEC Filings & Documents

Kyverna Therapeutics, Inc. (KYTX) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Aug 11, 2026·SEC

Material company update

Jul 27, 2026·SEC

Material company update

Jul 9, 2026·SEC

10-K Annual Reports

2
FY 2026

Mar 26, 2026·SEC

FY 2025

Mar 27, 2025·SEC

10-Q Quarterly Reports

6
FY 2026

Aug 11, 2026·SEC

FY 2026

May 12, 2026·SEC

FY 2025

Nov 12, 2025·SEC

Get notified when KYTX posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

KYTX Frequently Asked Questions

Kyverna Therapeutics, Inc. (KYTX) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
Is KYTX profitable?

No. Kyverna Therapeutics, Inc. (KYTX) reported a net loss of $157.8M over the trailing twelve months.

Dividend & Returns
What is KYTX's return on equity?

Kyverna Therapeutics, Inc. (KYTX) had a return on equity (ROE) of -86.9% over the trailing twelve months. A negative ROE means the company lost money over the period.

What is Kyverna Therapeutics, Inc.'s free cash flow?

Kyverna Therapeutics, Inc. (KYTX) had negative free cash flow of $151.3M over the trailing twelve months.

What if you invested $1,000 in KYTX back in 2021?

Total return calculator · dividends reinvested · 5+ years of data

See returns →